HC Wainwright Initiates Coverage on Immunic (NASDAQ:IMUX)

HC Wainwright began coverage on shares of Immunic (NASDAQ:IMUX) in a research report issued to clients and investors on Monday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $10.00 price target on the stock.

A number of other research firms also recently issued reports on IMUX. Leerink Partners reissued an “outperform” rating and issued a $5.00 target price on shares of Immunic in a research report on Monday, September 9th. B. Riley initiated coverage on shares of Immunic in a research note on Tuesday, August 27th. They set a “buy” rating and a $6.00 price target on the stock. EF Hutton Acquisition Co. I upgraded shares of Immunic to a “strong-buy” rating in a research note on Monday, September 16th. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. Finally, Leerink Partnrs raised Immunic to a “strong-buy” rating in a report on Monday, September 9th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $11.80.

Immunic Stock Performance

Shares of IMUX stock opened at $1.10 on Monday. Immunic has a 52 week low of $0.97 and a 52 week high of $2.11. The firm’s 50-day simple moving average is $1.40 and its two-hundred day simple moving average is $1.34. The firm has a market cap of $99.09 million, a price-to-earnings ratio of -0.89 and a beta of 1.88.

Insider Activity at Immunic

In other Immunic news, Director Richard Alan Rudick purchased 87,300 shares of the stock in a transaction on Tuesday, November 12th. The stock was acquired at an average cost of $1.15 per share, with a total value of $100,395.00. Following the completion of the purchase, the director now directly owns 87,300 shares of the company’s stock, valued at approximately $100,395. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of IMUX. State Street Corp grew its position in Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after acquiring an additional 11,642 shares during the last quarter. Virtu Financial LLC purchased a new stake in Immunic during the 1st quarter valued at $25,000. Jane Street Group LLC grew its holdings in Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after acquiring an additional 42,383 shares during the period. Finally, Ikarian Capital LLC raised its stake in shares of Immunic by 258.3% during the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after acquiring an additional 1,162,378 shares during the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.